Skip to content

History Of PharmaMar’s Orphan Drug Designation For Lurbinectedin (PM01183) For Ovarian Cancer

November 18, 2012

       Here are the historical events for PharmaMar’s orphan drug Lurbinectedin (PM01183) for ovarian cancer : 

–  PharmaMar on August 20, 2012, receives FDA Orphan Drug Designation (ODD)  

–  On September 5, 2012, the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP), adopts a positive opinion for granting orphan drug status      

–  On October 1, 2012, PharmaMar presents a Poster Presentation at the 37th European Society for Medical Oncology (ESMO) Meeting held in Vienna 9/28 – 10/1/12    

–  On October 10, 2012, EMA grants orphan designation 

–  On November 7, 2012, PharmaMar presents 5 trial results for Lurbinectedin at the 24th EORTC-NCI-AACR Symposium on Molecular Targets & Cancer Therapeutics held in Dublin 11/6 -11/9/12  

–  On November 16, 2012, EMA publishes the public summary document of the opinion on orphan designation. 

       Lurbinectedin (PM01183) is currently in Phase II clinical trials for ovarian, lung, pancreatic, and breast cancers.   


PharmaMar Drug Development Pipeline  

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: